Related Experiment Video
Updated: Jun 26, 2026

Analysis of Nonhomologous End Joining and Homologous Recombination Efficiency in HEK-293T Cells Using GFP-Based Reporter Systems
Published on: February 2, 2024
In vitro non-homologous DNA end joining assays--the 20th anniversary
Elzbieta Pastwa1, Richard I Somiari, Mariusz Malinowski
1Department of Molecular Genetics, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. epastwa@csk.umed.lodz.pl
Abstract:
DNA double-strand breaks (DSBs) are the most serious forms of DNA damage in cells. Unrepaired or misrepaired DSBs account for some of the genetic instabilities that lead to mutations or cell death, and consequently, to cancer predisposition. In human cells non-homologous DNA end joining (NHEJ) is the main repair mechanism of these breaks. Systems for DNA end joining study have been developing during the last 20 years. New assays have some advantages over earlier in vitro DSBs repair assays because they are less time-consuming, allow the use of clinical material and examination of the joining DNA ends produced physiologically in mammalian cells. Proteins involved in NHEJ repair pathway can serve as biomarkers or molecular targets for anticancer drugs. Results of studies on NHEJ in cancer could help to select potent repair inhibitors that may selectively sensitize tumor cells to ionizing radiation (IR) and chemotherapy. Here, we review the principles and practice of in vitro NHEJ assays and provide some insights into the future prospects of this assay in cancer diagnosis and treatment.
Insights
DNA double-strand breaks (DSBs) are critical DNA damage. New in vitro assays for non-homologous DNA end joining (NHEJ) repair are vital for cancer diagnosis and treatment strategies.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- DNA double-strand breaks (DSBs) represent the most severe DNA damage.
- Defective DSB repair contributes to genetic instability, mutations, and cancer.
- Non-homologous DNA end joining (NHEJ) is the primary repair pathway in human cells.
Purpose of the Study:
- To review the principles and practices of in vitro NHEJ assays.
- To explore the application of NHEJ assays in cancer diagnosis and treatment.
- To highlight the potential of NHEJ proteins as biomarkers and therapeutic targets.
Main Methods:
- Review of existing literature on in vitro DNA end joining assays.
- Comparison of new and older DSB repair assays.
- Analysis of NHEJ pathway proteins in the context of cancer.
Main Results:
- Modern in vitro NHEJ assays are faster and utilize clinical material.
- These assays allow examination of physiologically produced DNA ends in mammalian cells.
- NHEJ pathway proteins show promise as biomarkers and targets for anticancer drugs.
Conclusions:
- In vitro NHEJ assays have advanced significantly, offering practical advantages.
- Understanding NHEJ in cancer can guide the development of targeted therapies.
- NHEJ assays hold potential for improving cancer diagnosis and treatment strategies.
Related Concept Videos
Homologous Recombination
Homologous Recombination
In vitro Mutagenesis
Fixing Double-strand Breaks
Fixing Double-strand Breaks
In-vitro Mutagenesis

